PRESS RELEASE published on 07/30/2026 at 21:30, 1 month 7 days ago Informations privilégiées / Autres communiqués Poxel publie son chiffre d'affaires pour le deuxième trimestre 2026 et annonce le report de la publication des comptes 2025. Les ventes de TWYMEEG® au Japon en forte croissance Chiffre D'affaires Croissance Report Poxel TWYMEEG
PRESS RELEASE published on 07/30/2026 at 21:30, 1 month 7 days ago Inside Information / Other news releases Poxel publishes Q2 2026 turnover & delays 2025 financial statements release. TWYMEEG(R) net sales up in Japan, reaching 2.9 billion yen; royalty rate to increase Financial Statements Turnover Royalties Poxel TWYMEEG
BRIEF published on 06/10/2026 at 20:18, 2 months 26 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 2 months 26 days ago Poxel nomme Yves Decadt PDG pour faire progresser ses objectifs stratégiques Partenariats Stratégiques Biopharmaceutique Poxel Iméglimine Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 2 months 26 days ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 2 months 26 days ago Poxel nomme Yves Decadt comme nouveau Directeur Général Partenariats Stratégiques Biopharmaceutique Plan De Continuation Poxel Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 2 months 26 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 2 months 26 days ago Informations privilégiées / Autres communiqués Poxel nomme Yves Decadt Directeur Général pour accélérer la valorisation du portefeuille et les partenariats stratégiques. Continuité et ambition commerciale confirmée Partenariats Poxel PXL065 Iméglimine Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 5 months 6 days ago Poxel vend le PXL770 à Scynexis pour un montant pouvant atteindre 196 millions de dollars Biopharmaceutique Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 5 months 6 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
Published on 09/05/2026 at 04:05, 2 days 3 hours ago Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 2 days 8 hours ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 2 days 8 hours ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 2 days 9 hours ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 2 days 17 hours ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/07/2026 at 07:30, 17 minutes ago Hannover Re sees profitable growth opportunities in an increasingly challenging market environment
Published on 09/07/2026 at 07:00, 47 minutes ago Swiss Re sees growing protection needs as risks become more complex and interconnected
Published on 09/07/2026 at 07:00, 47 minutes ago Nouvelle hausse du résultat au premier semestre 2026
Published on 09/07/2026 at 07:00, 47 minutes ago R&S Group announces changes in the Executive Committee
Published on 09/04/2026 at 18:57, 2 days 12 hours ago Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 18:57, 2 days 12 hours ago Déclaration hebdomadaire d'opérations effectuées du 1er au 4 septembre 2026
Published on 09/04/2026 at 18:15, 2 days 13 hours ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/04/2026 at 18:15, 2 days 13 hours ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/04/2026 at 18:15, 2 days 13 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES AOÛT 2026
